12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Company News  |  Deals

Endo, Paladin deal

Endo is acquiring fellow specialty pharma Paladin in a cash and stock deal that the companies said values Paladin at C$77 per share, or about US$1.6 billion. Paladin shareholders will receive 1.6331 shares in the combined company, which is about 98% of the total purchase price, and C$1.16 in cash for each Paladin share held, or about C$23.9 million ($22.9 million). The C$77 price is a 20% premium to Paladin's close of C$63.91 on Nov....

Read the full 354 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >